The Food and Drug Administration has again spurned a cell therapy from Capricor Therapeutics, concluding that even a revised application didn’t clearly prove the treatment can help people with Duchenne muscular dystrophy.
In a statement Friday, Capricor revealed that the agency had issued a rejection letter for deramiocel, a cellular medicine it’s been developing for the progressive neuromuscular disorder. The regulator found certain “clinical deficiencies” in the submission and concluded that the data the company accumulated wasn’t “sufficient to establish substantial evidence of effectiveness,” Capricor said.
The agency, in a separate statement, accused Capricor of “serious data integrity violations” in the key study underlying its submission. Those issues — which included violations of study blinding protocols and after-the-fact changes to the statistical analysis plan — compromised Capricor’s findings, the FDA said.
“This was not a decision made lightly. Upholding rigorous evidentiary standards is precisely how the FDA protects patients, particularly those living with rare diseases, from interventions whose benefits have not been sufficiently established,” the regulator added.
“We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval,” countered CEO Linda Marbán, in Capricor’s statement. “We are reviewing the letter carefully and will share next steps once we have completed our evaluation.”
Deramiocel is made from donor-derived heart cells able to preserve certain cardiac and muscle function. Capricor had initially developed the therapy for a fatal, heart-related complication of Duchenne, and early testing showed deramiocel's potential to help the heart pump blood.
Capricor aimed for an approval based on results from a small trial and data from a historical study of heart function. Yet in July 2025, FDA officials rejected deramiocel, saying the company hadn't proven the therapy’s effectiveness and needed additional data. Capricor claimed to have been blindsided by the ruling.
“We are surprised by this decision by the FDA,” Marbán said in a statement at the time. Marbán added that the company had followed the agency's guidance and that the review had previously advanced with “no major issues.”
Capricor soon after announced that the FDA would reconsider the rejection based on new data from a late-stage study of deramiocel called “HOPE-3.” Last December, it revealed the treatment hit both of its main objectives in that study, helping preserve upper limb as well as heart function.
Those claims were intensely debated when the FDA convened a panel of experts to review Capricor's application in July. In briefing documents ahead of the meeting, FDA scientists argued deramiocel had actually failed the trial and tinkered with statistical analyses to produce a more compelling story. Capricor countered and said that agency staff relied on an outdated analysis.
The same day, HOPE-3 study results were published in The Lancet and conflicted with claims Capricor had previously made, forcing the company to issue a clarification in a regulatory filing.
The advisory committee ultimately sided with the FDA's assessment, with a majority of panelists concluding testing hadn't shown clear evidence of deramiocel's effectiveness. Panelists instead expressed more support for its potential impact on upper limb function.
The FDA, which originally sought to respond to Capricor by late August, extended its review of deramiocel to Nov. 22 after Capricor said it would instead seek clearance in a “refined” indication “focused on upper limb function.” More than two dozen trial investigators and physicians also penned a letter of support for approval to regulators in recent weeks.
Deramiocel’s review is “clearly a case where regulatory flexibility can be applied,” that group wrote. Rejection “would signal complete inflexibility on the part of the agency, contradicting the core values articulated” by its stance on rare disease drug reviews.
Under previous FDA leadership, a handful of drugmakers claimed to have been stunned by a sudden shift in regulatory guidance. Yet since the resignations of ex-commissioner Marty Makary and top deputy Vinay Prasad, U.S. regulators have changed their stance on a number of these decisions. They've also taken steps to show the agency will be more flexible in evaluating rare disease treatments.
“[The] FDA approaches rare disease applications with every intention of finding a path forward,” it said Friday, upon rejecting Capricor’s application. “[H]owever, flexibility in regulatory approach cannot come at the cost of the foundational requirement that the data underlying an approval decision be reliable.”